Inclusion Criteria:

1. Subjects must provide written informed consent prior to performance of study-specific
procedures or assessments, and must be willing to comply with treatment and
follow-up.

2. Age ≥ 18 years

3. The patient has histologically or cytologically confirmed epithelial ovarian cancer,
primary peritoneal carcinoma, fallopian tube cancer

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

5. The patient has completed at least 4 CYCLES OF one and up to two platinum-containing
regimens (involving cisplatin or carboplatin),for the management of this condition.
Treatment may have included intraperitoneal therapy, consolidation or extended
therapy administered after surgical or nonsurgical assessment.

6. The patient must have a platinum-free interval of ≤ 6 months after the final dose of
primary or subsequent platinum-based therapy.

Patients must have platinum-resistant disease,(defined as progression within <6
months from completion of a minimum of 4 platinum therapy cycles. The date should be
calculated from the last administered dose of platinum therapy.

7. The patient has at least one unidimensionally measurable target lesion (≥ 20 mm or ≥
10 mm by spiral computed tomography [CT] or magnetic resonance imaging [MRI]), as
defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines V 1.1.

8. Previously archived tumor tissue from either the primary or metastatic tumor
(paraffin block or 10 unstained slides) should be collected prior to administration
of the first dose of study therapy and stored at a secure central laboratory.

9. Adequate organ system function

10. Women of child bearing potential should be using an effective method of contraception
(complete abstinence, any intrauterine device (IUD) with published data showing that
the lowest expected failure rate is < 1 % per year; or any other methods with
published data showing that the lowest expected failure rate is less than 1 % per
year) before entry into the study and throughout the same and for 6 months after
ending the study. Women of childbearing potential must have a negative test serum or
urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of beta human
chorionic gonadotropin [β-HCG]) within 7 days prior to randomization.

11. Able to swallow oral compound.

12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory
tests and other study procedures.

Exclusion Criteria:

1. Other malignancy within the last 5 years, except for adequately treated carcinoma in
situ of the cervix or squamous carcinoma of the skin, or adequately controlled
limited basal cell skin cancer.

2. Previous treatment with >2 anticancer regimens for ovarian cancer

3. Prior treatment with any antiangiogenic treatment (i.e. Bevacizumab)

4. Patients with platinum-refractory disease defined as those patients progress during
platinum-based therapy.

5. History or clinical evidence of central nervous system (CNS) metastases or
leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
metastases, are asymptomatic, and have had no requirement for steroids or
anti-seizure medication for 6 months prior to first dose of study drug. Screening
with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging
[MRI]) is required only if clinically indicated or if the subject has a history of
CNS metastases.

6. Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding including, but not limited to:

- Active peptic ulcer disease

- Known intraluminal metastatic lesion/s with risk of bleeding

- Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn's disease), or other
gastrointestinal conditions with increased risk of perforation

- History of bowel obstruction, including sub-occlusive disease, related to the
underlying disease and history of abdominal fistula, gastrointestinal
perforation, or intra-abdominal abscess within 28 days prior to beginning study
treatment.

- active episodes of intestinal pseudo-obstruction

7. Clinically significant gastrointestinal abnormalities that may affect absorption of
investigational product including, but not limited to:

- Malabsorption syndrome

- Major resection of the stomach or small bowel.

- Grade 3 diarrhoea

8. Presence of uncontrolled infection.

9. Corrected QT interval (QTc) > 480 msecs using Bazett's formula

10. History of any one or more of the following cardiovascular conditions within the past
6 months:

- Cardiac angioplasty or stenting

- Myocardial infarction

- Unstable angina

- Coronary artery bypass graft surgery

- Symptomatic peripheral vascular disease

- Class II, III or IV congestive heart failure, as defined by the New York Heart
Association (NYHA

11. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg
or diastolic blood pressure (DBP) of ≥ 90mmHg] instead an anti-hypertensive
treatment.

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior
to study entry. BP must be assessed using the following recommendations:

Once a patient has had an elevated blood pressure reading (> 140/80mmHg) this should
be confirmed with another measurement, done locally if possible, either by the
patients local doctor, or by home monitoring if available. Patients should continue
to have their blood pressure monitored, at least weekly, until it becomes controlled
(i.e. ≤ 140/80mmHg on 2 separate occasions, at least one week apart).
Anti-hypertension medication changes, such as initiation of therapy, dose increases
of existing therapies, or addition of other anti-hypertensive agents, should be done
if the blood pressure remains high at 2 consecutive readings, at least 24 hours
apart. Please, refer to guidance regarding the management of hypertension for the
patient's local doctor for further information.

12. History of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6
months.

Note: Subjects with recent DVT who have been treated with therapeutic
anti-coagulating agents for at least 6 weeks are eligible

13. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
placement not considered to be major).

14. Prior minor surgery within 7 days prior to first dose of study drug

15. Evidence of active bleeding or bleeding diathesis.

16. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

17. Hemoptysis within 6 weeks of first dose of study drug.

18. Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance to study procedures.

19. Unable or unwilling to discontinue use of prohibited medications for at least 14 days
or five half-lives of a drug (whichever is longer) prior to the first dose of study
drug and for the duration of the study.

20. Treatment with any of the following anti-cancer therapies:

radiation therapy, surgery or tumor embolization within 14 days prior to the first
dose of pazopanib OR chemotherapy, immunotherapy, biologic therapy, investigational
therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is
longer) prior to the first dose of pazopanib

21. Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
progressing in severity, except alopecia.

22. Women who are pregnant or breast-feeding